← Back to Search

Procedure

Ablative Therapy for Gastrointestinal Cancer (LIVELONG Trial)

N/A

Recruiting

Led By Edward Kim, MD, PhD

Research Sponsored by University of California, Davis

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Age ≥18 years at time of consent.

≤ 5 progressing or new metastatic lesions.

Timeline

Screening 3 weeks

Treatment Varies

Follow Up up to 5 years from the first day of ablative local therapy

Awards & highlights

LIVELONG Trial Summary

This trial studies the benefit of adding locally ablative therapies to systemic therapy for solid tumors that have not spread widely. Outcome measure is time to treatment failure.

Who is the study for?

The LIVELONG trial is for adults over 18 with certain gastrointestinal cancers, like colorectal or stomach cancer, who have seen benefits from their current systemic therapy. They should have no more than five new or worsening metastatic lesions and be able to continue their present treatment after a short break for local therapy.Check my eligibility

What is being tested?

This phase 2 study tests if adding local ablative therapies (targeted treatments to destroy tumors) to ongoing systemic therapy can extend the time before treatment fails in patients with limited progression of gastrointestinal cancers.See study design

What are the potential side effects?

While specific side effects are not listed, locally ablative therapies may include risks such as pain at the treatment site, fatigue, skin reactions, and potential damage to nearby organs or tissues.

LIVELONG Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I am 18 years old or older.

Select...

I have 5 or fewer new or growing cancer spots.

Select...

My cancer is in the colon, rectum, or appendix.

Select...

My cancer type has been confirmed through testing.

LIVELONG Trial Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ up to 5 years from the first day of ablative local therapy

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~up to 5 years from the first day of ablative local therapy

This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years from the first day of ablative local therapy for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Number of participants with controlled disease

Secondary outcome measures

Median overall survival

Number of participants experiencing grade ≥ 3 adverse events attributable to ablative local therapy

Time to treatment failure

LIVELONG Trial Design

1Treatment groups

Experimental Treatment

Group I: Ablative local therapyExperimental Treatment1 Intervention

Stereotactic ablative radiotherapy (SABR) or interventional radiology (IR) ablation therapy

0 / 4Eligibility criteria met

Find a Location

Who is running the clinical trial?

University of California, DavisLead Sponsor

911 Previous Clinical Trials

4,709,219 Total Patients Enrolled

National Cancer Institute (NCI)NIH

13,672 Previous Clinical Trials

40,926,141 Total Patients Enrolled

Edward Kim, MD, PhDPrincipal InvestigatorUniversity of California, Davis

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there any vacancies available for this research initiative?

"Affirmative. According to information found on clinicaltrials.gov, the trial in question is still actively seeking participants. It was initially posted on October 5th 2023 and underwent its latest update a fortnight later; 300 subjects are required at one medical site for this study's successful completion."

Answered by AI

How many participants are being invited to join this experiment?

"Affirmative. The information provided on clinicaltrials.gov confirms that this experiment, initially posted on October 5th 2023, is actively recruiting its 300 planned participants from 1 medical centre."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Locally ablatIVe thErapy for oLigo-progressive gastrOintestiNal maliGnancies (LIVELONG)

Edward Kim 2023. "Locally ablatIVe thErapy for oLigo-progressive gastrOintestiNal maliGnancies (LIVELONG)". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT06101277.